Milrinone is a phosphodiesterase 3 (PDE3) inhibitor [1]. It works by selectively inhibiting PDE3 in cardiac and vascular smooth muscle [2]. This inhibition leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) [2][3].
How does increased cAMP affect the heart and blood vessels?
The elevated cAMP levels in cardiac muscle cells result in positive inotropic effects, meaning the heart muscle contracts more forcefully [2]. Simultaneously, increased cAMP in vascular smooth muscle cells causes vasodilation, leading to a widening of blood vessels [2]. This dual action of increasing cardiac contractility and decreasing vascular resistance helps to improve cardiac output [2].
What are the main uses of milrinone?
Milrinone is primarily used for the short-term management of acute decompensated heart failure in patients who have not responded adequately to other therapies [1][4]. It is administered intravenously [4].
What is the mechanism of action for other heart failure medications?
Other medications used for heart failure may have different mechanisms of action. For example, beta-blockers work by blocking the effects of adrenaline, slowing the heart rate and reducing the heart's workload [5]. ACE inhibitors and angiotensin II receptor blockers (ARBs) work by relaxing blood vessels and reducing fluid buildup by affecting the renin-angiotensin-aldosterone system [6]. Digoxin, another inotropic agent, increases the force of heart contractions by inhibiting the sodium-potassium pump [7].
When does milrinone's patent protection expire?
Information on the specific patent expiration dates for milrinone is available through resources like DrugPatentWatch.com [8]. Patent exclusivity determines when generic versions of a drug can enter the market [9].